Hair Loss Control Clinic Celebrates 25 Years

The Hair Loss Control Clinic celebrated its 25th anniversary in September 2011. Today, the company has more than 140 affiliated locations in 28 countries around the world. HLCC began as a provider of professional hair loss products and equipment to the medical industry and has more recently expanded into the salon and spa industries. It offers a multitherapeutic approach to hair loss, manufacturing its own system of oral and topical hair growth nutritionals as well as haircare maintenance products that are specifically formulated for the treatment of hair loss.

International Physicians Honored

L’Oréal, parent company of LaRoche-Posay, and Galderma joined forces to honor civic-minded physicians at the International Awards for Social Responsibility in Dermatology, held during the 22nd World Congress of Dermatology in Seoul, South Korea. The awards were created to highlight and reward five community projects from five geographic zones—Europe, North America, Latin America, Asia Pacific and Africa. The honorees each received a $15,000 grant to continue their work. They are:

Cynosure Acquires HOYA ConBio

Cynosure, a developer of laser- and light-based aesthetic devices has acquired Freemont, California-based HOYA ConBio—a wholly owned subsidiary of Japan-based HOYA Corporation. Cynosure acquired the company for $24.5 million in cash. The acquisition will expand Cynosure’s portfolio of products to include HOYA ConBio’s proprietary PhotoAcoustic energy technology. In a letter to existing customers, Cynosure noted that it will market the company’s full line of lasers—including the popular Revlite and Medlite tattoo removal systems—under the name ConBio, a Cynosure Company.

Allergan Takes on New Rosacea Topical

Allergan has entered into a definitive agreement to acquire all outstanding shares and assets of privately owned dermatology company Vicept Therapeutics. Vicept’s lead investigational product, V-101, is a topical cream for the treatment of erythema associated with rosacea. It has achieved positive results in two randomized, placebo-controlled Phase II studies. The acquisition agreement includes a $75 million cash upfront payment by Allergan, plus up to an aggregate of $200 million in payments contingent upon achieving certain future development and regulatory milestones.

Valeant Obtains Rights to Sculptra

Valeant Pharmaceuticals—a multinational specialty pharmaceutical company—and its subsidiary Valeant International have signed an agreement to acquire Dermik, the United States and Canada-based dermatology unit of Sanofi. Dermik’s portfolio of products includes acne treatment Benzaclin, keratoses treatment Carac and Sculptra facial injectable treatment. As part of the agreement, Valeant will obtain worldwide rights to Sculptra Aesthetic (poly-L-lactic acid).

Sciton Enters Russia

Sciton, a manufacturer of laser- and light-based devices for the medical aesthetics market, has received product registration in Russia for two of its most popular systems—the JOULE expandable platform and the standalone BBLs BroadBand Light device. InMedTech will market, sell and service the devices in Russia per a strategic partnership agreement between the two companies. “The receipt of regulatory clearance in Russia for our products opens a large, new opportunity for us,” said Dan Negus, president of Sciton.

Photomedex To Merge With Radiancy

Photomedex, a developer of excimer light, LED and skincare products, has announced a definitive merger agreement with Radiancy, manufacturer of professional and home-use aesthetic and dermatologic devices, and PHMB Merger Sub, a wholly owned subsidiary of Photomedex. Under the terms of the agreement, Radiancy will provide cash for Photomedex to repurchase convertible notes and accrued interest, which—at the close of the agreement—was valued at $22.4 million. Merger Sub will merge into Radiancy, and Radiancy will become a wholly owned subsidiary of Photomedex.

Epionce Honored

Dr. Carl Thornfeldt accepts the Small Business of the Year Award

Episciences, the maker of Epionce skincare products, has received the Small Business of the Year Award from the Boise Metro Chamber of Commerce. The awards were developed to recognize companies that havea history of outstanding business practices in the Boise, Idaho community. Judging criteria included:
• Staying power
• Growth in number of employees
• Increase in sales and/or unit volume
• Innovativeness of product or service offered
• Response to adversity
• Contributions by company to aid community-oriented projects

Allergan Assay Milestone May Reduce Animal Testing

The United States Food and Drug Administration has approved a fully in vitro cell-based assay developed by Allergan for use in the stability and potency testing of Botox (onabotulinumtoxinA) and Botox Cosmetic. The FDA approval follows more than a decade of research and development by Allergan. As other regulatory agencies around the world approve this new assay, Allergan estimates that it could reduce the use of animal-based assay testing for Botox and Botox Cosmetic by up to 95% or more over the next three years.